FDA Holds Up HeartWare LVAD Trial In Less Advanced Heart Failure Patients

Investigators for the REVIVE-IT pilot study received a second deficiency letter from FDA May 11; researchers say they continue to work with the agency to move forward on the 100-patient, randomized trial.